Psychiatry Research: Neuroimaging
Volume 162, Issue 3 , Pages 230-235 , 15 April 2008

Greater availability of dopamine transporters in patients with major depression — A dual-isotope SPECT study

  • Yen Kuang Yang

      Affiliations

    • Department of Psychiatry National Cheng Kung University Hospital, Tainan, Taiwan
    • Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, College of Medicine, National Cheng Kung University 138 Sheng Li Road, Tainan 70403, Taiwan. Tel.: +886 6 2353535x5213; fax: +886 6 2759259.
    • ,
  • Tzung Lieh Yeh

      Affiliations

    • Department of Psychiatry National Cheng Kung University Hospital, Tainan, Taiwan
    • Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • ,
  • Wei Jen Yao

      Affiliations

    • Department of Nuclear Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • ,
  • I Hui Lee

      Affiliations

    • Department of Psychiatry National Cheng Kung University Hospital, Tainan, Taiwan
    • Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • ,
  • Po See Chen

      Affiliations

    • Department of Psychiatry National Cheng Kung University Hospital, Tainan, Taiwan
    • Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • ,
  • Nan Tsing Chiu

      Affiliations

    • Department of Nuclear Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • ,
  • Ru Band Lu

      Affiliations

    • Department of Psychiatry National Cheng Kung University Hospital, Tainan, Taiwan
    • Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Received 12 December 2006 ,Revised 18 June 2007 ,Accepted 26 August 2007.

References 

  1. Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier I, et al. Low blood cholesterol and low platelet serotonin levels in violent suicide attempters. Biological Psychiatry. 1999;45:1066–1069
  2. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. Journal of Affective Disorders. 2005;89:115–123
  3. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99mTc] TRODAT-1 SPECT imaging. The American Journal of Psychiatry. 2003;160:1836–1841
  4. Cyr M, Morissette M, Barden N, Beaulieu S, Rochford J, Di Paolo T. Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants. Neuroscience. 2001;102:151–158
  5. D'haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biological Psychiatry. 1994;35:128–132
  6. Delgado PL. Depression: the case for a monoamine deficiency. The Journal of Clinical Psychiatry. 2000;61:7–11
  7. Dresel SH, Kung MP, Huang XF, Plossl K, Hou C, Meegalla SK, et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 1999;40:660–666
  8. Ebert D, Feistel H, Loew T, Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology. 1996;126:91–94
  9. Elhwuegi AS. Central monoamines and their role in major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2004;28:435–451
  10. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry. 1992;49:538–544
  11. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. European Journal of Pharmacology. 1996;298:27–30
  12. Ikawa K, Watanabe A, Kaneno S, Toru M. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. European Journal of Pharmacology. 1994;250:261–266
  13. Kao, P.F., Tzen, K.Y., Wey, S.P., 2001. [99mTc]TRODAT-1/ [123I]-IBZM Simultaneous Dual-isotope SPECT in Studying Pre- and Post-synaptic Dopamine Binding Sites: from Phantom Studies to Clinical Applications. (The second year project). Atomic Energy Council. Report nr NSC90-NU-7-182A-002.
  14. Kilbourn MR, Sherman PS, Pisani T. Repeated reserpine administration reduces in vivo [18F] GBR 13119 binding to the dopamine uptake site. European Journal of Pharmacology. 1992;216:109–112
  15. Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. Journal of Pharmacology and Experimental Therapeutics. 2001;298:129–140
  16. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biological Psychiatry. 2002;52:740–748
  17. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123]IBZM SPECT. Psychiatry Research. Neuroimaging. 1999;90:91–101
  18. Ko HC, Lu RB, Shiah IS, Hwang CC. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biological Psychiatry. 1997;41:774–781
  19. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology. 1999;144:282–285
  20. Laasonen-Balk T, Viinamaki H, Kuikka JT, Husso-Saastamoinen M, Lehtonen J, Tiihonen J. 123I-beta-CIT binding and recovery from depression — a six-month follow-up study. European Archives of Psychiatry and Clinical Neuroscience. 2004;254:152–155
  21. Laine TP, Ahonen A, Rasanen P, Tiihonen J. Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Research. Neuroimaging. 1999;90:153–157
  22. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner HW. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5:251–260
  23. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism. 2000;3:423–451
  24. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, et al Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biological Psychiatry. 1998;44:1090–1098
  25. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport. 2001;12:4121–4125
  26. Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychological Medicine. 2001;31:1467–1473
  27. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biological Psychiatry. 2001;50:313–322
  28. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychological Medicine. 1997;27:1247–1256
  29. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry. 1998;59:22–33
  30. Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. Journal of Clinical Psychopharmacology. 2004;24:11–17
  31. Spreux-Varoquaux O, Gailledreau J, Vanier B, Bothua D, Plas J, Chevalier JF, et al. Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine?. Biological Psychiatry. 1996;40:465–473
  32. Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry. 2002;35:175–181
  33. Yang YK, Chiu NT, Chen CC, Chen M, Yeh TL, Lee IH. Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls. Psychiatry Research. Neuroimaging. 2003;123:191–197
  34. Yang YK, Lung Y, Yeh TL, Chiu NT, Chen PS, Lee IH. Associated attenations of striatal of striatal dopamine D2/D3 receptor and transporter binding in drug naive patients with schizophrenia: a dual-isotope SPECT study. The American Journal of Psychiatry. 2004;161:1496–1498

PII: S0925-4927(07)00174-6

doi: 10.1016/j.pscychresns.2007.08.008

Psychiatry Research: Neuroimaging
Volume 162, Issue 3 , Pages 230-235 , 15 April 2008

Article Tools

* Image Usage & Resolution